[The clinical cardiac electrophysiologic effects of tetrandrine].
Acute electrophysiologic effects of intravenous tetrandrine were evaluated with programmed electrical stimulation in 20 patients. The results showed that: (1) tetrandrine significantly lengthened SCL and A-H interval (P < 0.001), AVNERP, AVNWCL and SPERP (P < 0.05). It did not affect the SACT, SNRT, P-A, H-V, Q-T intervals and the ERP of atrium, ventricle and accessory pathway significantly. Its electrophysiologic property is similar to verapamil. (2) It prevented induction of SVT in 4 cases, 4 cases of sustained SVT were no longer sustained, the effective rate is 85.7%. The curative effect on AVNRT (100%) is better than that on AVRT (71.4%). (3) No severe side effect was observed. Therefore, tetrandrine is an effective drug for the treatment of SVT.
Li
W H
WH
Institute of Cardiovascular Diseases, Tong Ji Medical University, Wuhan.
D000293:Adolescent; D000328:Adult; D000470:Alkaloids / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D044182:Benzylisoquinolines; D004594:Electrophysiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011226:Pre-Excitation Syndromes / Q000188:drug therapy / Q000503:physiopathology; D013617:Tachycardia, Supraventricular / Q000188:drug therapy* / Q000503:physiopathology
D000470:Alkaloids; D000889:Anti-Arrhythmia Agents; D044182:Benzylisoquinolines; C009438:tetrandrine